1
|
Chambers GP, Kelton W, Smolenski G, Cuttance E. Impact of prepartum administration of a vaccine against infectious calf diarrhea on nonspecific colostral immunoglobulin concentrations of dairy cows. J Anim Sci 2022; 100:6604626. [PMID: 35678245 DOI: 10.1093/jas/skac212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2022] [Accepted: 06/06/2022] [Indexed: 11/14/2022] Open
Abstract
Passive transfer of colostral immunoglobulins from the cow to the calf is essential for calf health. The objective of this study was to determine if prepartum administration of a vaccine stimulates increased concentrations of colostral immunoglobulins of dairy cows beyond what is explained by vaccine-specific immunoglobulins. A prospective cohort study was conducted on a spring-calving commercial dairy farm that had a policy of only vaccinating cows with even ear tag numbers with a calf diarrhea vaccine, while cows with odd ear tag numbers were left unvaccinated. Cows in the vaccinated group (even ear tag numbers, n=204) received a sensitizer and booster vaccination with a vaccine against bovine rotavirus (serotypes G6 and G10), bovine coronavirus and E. coli having the K99 pili adherence factor. A sensitizer was given because the study vaccine was different to the vaccine previously used. Cows in the control group (odd ear tag numbers, n=194) received a 2 mL subcutaneous sterile saline solution. Both groups received two treatments at a three-week interval, completing the treatments approximately two weeks prior to the planned start of calving. During the calving period, technicians separated calves from cows immediately after parturition and prior to suckling, and cows were completely milked out within six hours of parturition. Vaccine-specific, total, and nonvaccine-specific (total minus vaccine-specific) concentrations of immunoglobulin classes A, G1, G2a and M (IgA, IgG1, IgG2a and IgM respectively) were quantified by mass spectrometry for 20 colostrum samples from each treatment group. Predicted mean non-vaccine-specific colostral IgM concentrations were 8.76 (95% CI =7.18-10.67) and 5.78 (95% CI =4.74-7.05) mg/ml for vaccinated and control cows respectively (p =0.005). Predicted mean non-vaccine-specific colostral IgG1 concentrations were 106.08 (95% CI =92.07-120.08) and 95.30 (95% CI =81.30-109.31) mg/ml among vaccinated and control cows respectively, however these means were not significantly different (p=0.278). It is thus possible that the vaccine, in addition to specifically managing infectious calf diarrhea, may also have non-specific benefits by improving colostrum quality through increased non-vaccine-specific colostrum IgM concentrations. Further research is necessary to determine the mechanism for these preliminary findings, whether the effect may occur in other immunoglobulin classes, and what impacts it may have on calf health outcomes.
Collapse
Affiliation(s)
- Gregory P Chambers
- Zoetis New Zealand Limited, Level 5, 8 Mahuhu Crescent, Auckland 1010, New Zealand
| | - William Kelton
- Te Huataki Waiora School of Health, The University of Waikato, Hamilton 3240, New Zealand
| | - Grant Smolenski
- MS3 Solutions Ltd., Ruakura Research Centre, Hamilton 3240, New Zealand
| | - Emma Cuttance
- EpiVets, 565 Mahoe Street, Te Awamutu, 3800, New Zealand
| |
Collapse
|
2
|
Immune response of mature cows subjected to annual booster vaccination against neonatal calf diarrhoea with two different commercial vaccines: A non-inferiority study. Livest Sci 2017; 204:52-58. [PMID: 32288873 PMCID: PMC7102762 DOI: 10.1016/j.livsci.2017.08.011] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2017] [Revised: 08/11/2017] [Accepted: 08/11/2017] [Indexed: 12/19/2022]
Abstract
Neonatal calf diarrhoea can have important economic consequences. Scour vaccines are available against some of the most frequent pathogens responsible for this disease: Bovine Rotavirus (BoRV), Bovine Coronavirus (BoCV) and E. coli K99. In this multi-centre, randomised, blinded study, adult cows vaccinated with a trivalent vaccine marketed for years (Rotavec™ Corona, MSD Animal Health - RC) prior to last parturition were revaccinated 12–15 months later, prior to the upcoming parturition, with either a single injection of a recently marketed vaccine (Bovigen™ Scour, Virbac - BS), or RC. The aim of this trial was to verify whether BS is not inferior to RC for the stimulation of the immune response and the passive transfer to calves in these conditions. A total of 136 multiparous dairy cows, from 5 different herds and located in 3 countries (France, UK and Germany) were enrolled in the study. Sixty-five cows were vaccinated with BS and 71 with RC. Antibody levels, measured by competitive ELISA and represented as percentage of inhibition (PI), were assessed in the cow's serum (on the day of vaccination: D0 and on days 21, 42 and at calving), in the colostrum and in the serum of calves in the first week of life. Differences in means of PI between groups and the 95% confidence interval (CI) were calculated. The non-inferiority threshold was set at −10%. The relationships between antibody levels in the colostrum and the vaccination-calving interval (VCI) or the inter-booster vaccination interval (IBVI) were also analysed. All the lower margins of the 95% CI of the difference in means of PI, in all samples and for the 3 pathogens assessed, were above −10%. This result shows that BS is not inferior to RC for the stimulation of the immune response against BoRV, BoCV and E. coli K99 and the passive transfer of immunity to calves when this vaccine is administered to their dams previously vaccinated with RC. Furthermore, no correlation was found between PI values in the colostrum and the VCI or IBVI. The ratio of animals with a PI ≥ 95% in the colostrum, among cows with similar intervals, was not significantly different between groups, for all antigens tested. Therefore, this study shows that a single injection of the heterologous vaccine BS can be used as a booster in cattle previously vaccinated with RC. Vaccinating adult cows against NCD results in high antibody levels in the serum and in the colostrum. Vaccination between 9 to 4 weeks prior to the expected due date results in highest antibody levels. Time elapsed between two annual single injections does not have consequences on antibody levels. Two differently adjuvanted BoRV, BoCv and F5 vaccines, was not found statistically inferior.
Collapse
|
3
|
Bailey KE, Gilkerson JR, Browning GF. Equine rotaviruses--current understanding and continuing challenges. Vet Microbiol 2013; 167:135-44. [PMID: 23932076 PMCID: PMC7117381 DOI: 10.1016/j.vetmic.2013.07.010] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2013] [Revised: 07/04/2013] [Accepted: 07/07/2013] [Indexed: 11/20/2022]
Abstract
Equine rotaviruses were first detected in foals over 30 years ago and remain a major cause of infectious diarrhoea in foals. During this time, there has been substantial progress in the development of sensitive methods to detect rotaviruses in foals, enabling surveillance of the genotypes present in various horse populations. However, there has been limited epidemiological investigation into the significance of these circulating genotypes, their correlation with disease and the use of vaccination in these animal populations. Our knowledge of the pathogenesis of rotavirus infection in foals is based on a limited number of studies on a small number of foals and, therefore, most of our understanding in this area has been extrapolated from studies in other species. Questions such as the concentrations of rotavirus particles shed in the faeces of infected foals, both with and without diarrhoea, and factors determining the presence or absence of clinical disease remain to be investigated, as does the relative and absolute efficacy of currently available vaccines. The answer to these questions may help direct research into the development of more effective control measures.
Collapse
Affiliation(s)
- Kirsten E Bailey
- Centre for Equine Infectious Diseases, Faculty of Veterinary Science, The University of Melbourne, Parkville, Victoria 3010, Australia.
| | | | | |
Collapse
|
4
|
Antibody response in vaccinated pregnant mares to recent G3BP[12] and G14P[12] equine rotaviruses. Acta Vet Scand 2012; 54:63. [PMID: 23130609 PMCID: PMC3523035 DOI: 10.1186/1751-0147-54-63] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2012] [Accepted: 11/01/2012] [Indexed: 11/25/2022] Open
Abstract
Background Both the G3P[12] and the G14P[12] type of equine group A rotavirus (RVA) have recently become predominant in many countries, including Japan. G3 types are classified further into G3A and G3B. The G3A viruses have been circulating in Europe, Australia, and Argentina, and the G3B viruses have been circulating in Japan. However, only an inactivated vaccine containing a single G3BP[12] strain is commercially available in Japan. To assess the efficacy of the current vaccine against recently circulating equine RVA strains, we examined antibody responses in pregnant mares to recent G3BP[12] and G14P[12] strains by virus neutralization test. Findings After vaccination in five pregnant mares, the geometric mean serum titers of virus-neutralizing antibody to recent G3BP[12] strains increased 5.3- to 7.0-fold and were similar to that against homologous vaccine strain. Moreover, antibody titers to recent G14P[12] strains were also increased 3.0- to 3.5-fold. Conclusions These results suggest that inoculation of mares with the current vaccine should provide foals with virus-neutralizing antibodies against not only the G3BP[12] but also the G14P[12] RVA strain via the colostrum.
Collapse
|
5
|
Armah GE, Hoshino Y, Santos N, Binka F, Damanka S, Adjei R, Honma S, Tatsumi M, Manful T, Anto F. The global spread of rotavirus G10 strains: Detection in Ghanaian children hospitalized with diarrhea. J Infect Dis 2010; 202 Suppl:S231-8. [PMID: 20684709 DOI: 10.1086/653572] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
Abstract
From October 2003 through September 2004, a total of 289 stool samples were collected from children <5 years of age who had severe diarrhea at admission to or when visiting the emergency department at the Navrongo War Memorial Hospital in rural Ghana during a study on rotavirus disease burden. Rotavirus antigen was detected in 115 stool samples (39.8%) tested for rotavirus. Four rotavirus-positive samples were found to bear G10P[6] specificity by reverse-transcription polymerase chain reaction, polymerase chain reaction-enzyme-linked immunosorbent assay, and oligonucleotide microarray hybridization. Two of these strains further exhibited serotype G10 specificity by neutralization and subgroup II specificity by enzyme immunoassay and possessed long electropheretic patterns by polyacrylamide gel electrophoresis. Their VP7 genes shared a much closer nucleotide identity with other African human G10 strains (>97%) than with human G10 strain from Asia or South America (<86%) or animal strains (<85%). The VP8* genes of the Ghanaian G10 strains exhibited >94% identity to that of human P[6] virus strains and belonged to the P[6] lineage 1a. The deduced VP7 amino acid sequence showed that the Ghanaian strains were more closely related to human G10 strains than to animal G10 strains. The possession of the typical human subgroup II specificity and the P[6] specificity (frequently found in Ghana and the rest of Africa) and the marked similarity in the VP7 antigenic sites suggest that these G10 strains may have evolved through genetic reassortment between bovine and human strains.
Collapse
Affiliation(s)
- George E Armah
- Department of Electron Microscopy and Histopathology, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Ghana.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Yuan L, Honma S, Kim I, Kapikian AZ, Hoshino Y. Resistance to rotavirus infection in adult volunteers challenged with a virulent G1P1A[8] virus correlated with serum immunoglobulin G antibodies to homotypic viral proteins 7 and 4. J Infect Dis 2009; 200:1443-51. [PMID: 19785527 PMCID: PMC2760642 DOI: 10.1086/606116] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
BACKGROUND In a study performed in 1983, 18 adult volunteers received oral challenge with the virulent human rotavirus strain D (G1P1A[8],NSP4[B]). To identify correlates of resistance to rotavirus infection, we analyzed levels of serum immunoglobulin (Ig) A and IgG antibodies to various rotaviral antigens in 16 of the 18 volunteers. METHODS We used immunocytochemical assays that involved a total of 16 different recombinant baculoviruses, with each baculovirus expressing one of the following major serotype/genotype rotavirus proteins for the serologic assays: (1) viral protein (VP) 4 with P1A[8], P1B[4], P2A[6], P3[9], or P4[10] specificity; (2) VP7 with G1-G4 or G9 specificity; and (3) nonstructural viral protein (NSP) 4 with genotype A, B, C, or D specificity. RESULTS The prechallenge titers of IgG antibody to VP7 types G1, G3, G4, and G9; VP4 types P1A[8], P1B[4], P2A[6], and P4[10]; and NSP4 type [A] in the group of noninfected volunteers (n = 11) were significantly higher than those in the group of infected volunteers (n = 5; of these 5 volunteers, 4 were symptomatically infected). Moreover, logistic regression analysis showed that resistance to rotavirus infection most closely correlated with higher prechallenge titers of IgG antibody to homotypic VP7 (G1) and VP4 (P1A[8]). CONCLUSIONS These results suggest that protection against rotavirus infection and disease is primarily VP7/VP4 homotypic and, to a lesser degree, heterotypic.
Collapse
Affiliation(s)
- Lijuan Yuan
- Center for Molecular Medicine and Infectious Diseases, Department of Biomedical Sciences and Pathobiology, Virginia Polytechnic Institute and State University, 1410 Prices Fork Road, Blacksburg, VA 24061, USA (L.Y.)
| | - Shinjiro Honma
- Department of Pediatrics, Sapporo Medical University, Sapporo, Japan (S.H)
| | - Inyoung Kim
- Department of Statistics, Virginia Polytechnic Institute and State University, 410A Hutcheson Hall, Blacksburg, VA 24061 (I.K.)
| | - Albert Z. Kapikian
- Epidemiology Section, Laboratory of Infectious Disease, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892
| | - Yasutaka Hoshino
- Epidemiology Section, Laboratory of Infectious Disease, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892
| |
Collapse
|
7
|
Alkan F, Ozkul A, Oguzoglu TC, Timurkan MO, Caliskan E, Martella V, Burgu I. Distribution of G (VP7) and P (VP4) genotypes of group A bovine rotaviruses from Turkish calves with diarrhea, 1997-2008. Vet Microbiol 2009; 141:231-7. [PMID: 19854003 DOI: 10.1016/j.vetmic.2009.09.016] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2009] [Revised: 09/03/2009] [Accepted: 09/22/2009] [Indexed: 10/20/2022]
Abstract
Group A rotaviruses are major enteric pathogens of calves. In order to investigate the genetic diversity of bovine rotaviruses (BRVs), a collection of 53 BRVs, detected from diarrheic calves from several Turkish geographical areas, between 1997 and 2008 was analyzed by RT-PCR for specificities of the outer capsid proteins VP7 (G type) and VP4 (P type), for the first time. Overall, G6 was the predominant G type, detected in 40/53 samples (75.4%), while P[11] was the predominant P type, detected in 52/53 samples (98.1%). The most common VP7/VP4 combinations were G6P[11] (60.3%) and G10P[11] (24.5%). Mixed infections were identified in 7/53 samples (13.2%). In the VP7 region the G6P[11] viruses were similar to other ones detected worldwide, forming an independent G6 lineage, distantly related to the G6 gene of the vaccine G6P[1] strain NCDV (90.1% amino acid identity), and suggesting that G6P[11] viruses represent a genetically stable BRV strain. The study of G and P type diversity is pivotal to understand the efficacy of the existing rotavirus vaccines and to provide the basis of future prophylaxis tools against rotaviral diarrhea of calves.
Collapse
Affiliation(s)
- Feray Alkan
- Ankara University, Faculty of Veterinary Medicine, Irfan Bastug Cad, Diskapi, 06110 Ankara, Turkey.
| | | | | | | | | | | | | |
Collapse
|
8
|
Cao D, Igboeli B, Yuan L, Kapikian AZ, Ayers JL, Abinanti FR, Hoshino Y. A longitudinal cohort study in calves evaluated for rotavirus infections from 1 to 12 months of age by sequential serological assays. Arch Virol 2009; 154:755-63. [PMID: 19343476 DOI: 10.1007/s00705-009-0331-y] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2008] [Accepted: 01/21/2009] [Indexed: 11/28/2022]
Abstract
Using an immunocytochemical staining assay involving six different recombinant baculoviruses with each expressing one of the major bovine rotavirus VP7 (G6, G8 and G10) and VP4 (P6[1], P7[5] and P8[11]) serotypes, we analyzed IgG antibody responses to individual proteins in archival serum samples collected from 31 calves monthly from 1 to 12 months of age during 1974-1975 in Higley, Arizona. Seroresponses to VP7 and VP4, as determined by a fourfold or greater antibody response, were not always elicited concurrently following infection: in some calves, (1) seroresponses to VP7 were detected earlier than to VP4 or vice versa; and (2) a subsequent second seroresponse was detected for VP7 or VP4 only. In addition, a second infection was more likely to be caused by different G and/or P types. Analyses of serum samples showed that the most frequent G-P combination was G8P6[1], followed by G8P7[5], G8P8[11] and G6P6[1].
Collapse
Affiliation(s)
- Dianjun Cao
- Epidemiology Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 50, Room 6308, Bethesda, MD 20892, USA
| | | | | | | | | | | | | |
Collapse
|
9
|
Hoshino Y, Jones RW, Chanock RM, Kapikian AZ. Generation and characterization of six single VP4 gene substitution reassortant rotavirus vaccine candidates: each bears a single human rotavirus VP4 gene encoding P serotype 1A[8] or 1B[4] and the remaining 10 genes of rhesus monkey rotavirus MMU18006 or bovine rotavirus UK. Vaccine 2002; 20:3576-84. [PMID: 12297404 DOI: 10.1016/s0264-410x(02)00313-4] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
The global disease burden of rotavirus diarrhea in infants and young children has stimulated interest in the biological and clinical characteristics of these agents, leading to intensive efforts to develop a vaccine. A rhesus rotavirus (RRV)-based quadrivalent vaccine ("RotaShield") was licensed and administered to about 1 million infants and found to be highly effective. However, it was withdrawn because of a link with intussusception. This vaccine was developed according to a modified "Jennerian" approach in which one of the two major outer capsid proteins (VP7) shares neutralization specificity with one of the four epidemiologically important human rotavirus serotypes. The other outer capsid protein (VP4) is derived solely from RRV and is distinct from the VP4 of the four human rotavirus serotypes of epidemiologic importance. In an effort to further increase the immunogenicity of the existing VP7-based RRV quadrivalent vaccine, we generated three single VP4 gene substitution reassortant rotavirus candidate vaccines, each of which bears a single human rotavirus VP4 gene encoding P serotype 1A[8] or 1B[4] specificity while the remaining 10 genes are derived from the rhesus rotavirus. By incorporating one or two of these strains into the quadrivalent vaccine, a pentavalent or hexavalent RRV-based vaccine could be formulated thus providing antigenic coverage not only for VP7 serotype 1, 2, 3 and 4 but also for VP4 serotype 1A[8] or 1B[4], thus possibly augmenting its immunogenicity. Similarly, three single VP4 gene (P1A[8] or P1B[4]) substitution reassortants have also been generated in a background of 10 bovine (UK) rotavirus genes for addition to a second generation UK-based quadrivalent vaccine.
Collapse
Affiliation(s)
- Yasutaka Hoshino
- Epidemiology Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 50, Room 6308, 50 South Drive MSC 8026, Bethesda, MD 20892-8026, USA.
| | | | | | | |
Collapse
|
10
|
Crawford SE, Estes MK, Ciarlet M, Barone C, O'Neal CM, Cohen J, Conner ME. Heterotypic protection and induction of a broad heterotypic neutralization response by rotavirus-like particles. J Virol 1999; 73:4813-22. [PMID: 10233942 PMCID: PMC112524 DOI: 10.1128/jvi.73.6.4813-4822.1999] [Citation(s) in RCA: 59] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/1998] [Accepted: 02/24/1999] [Indexed: 11/20/2022] Open
Abstract
The recognition that rotaviruses are the major cause of life-threatening diarrheal disease and significant morbidity in young children has focused efforts on disease prevention and control of these viruses. Although the correlates of protection in children remain unclear, some studies indicate that serotype-specific antibody is important. Based on this premise, current live attenuated reassortant rotavirus vaccines include the four predominant serotypes of virus. We are evaluating subunit rotavirus vaccines, 2/6/7-VLPs and 2/4/6/7-VLPs, that contain only a single VP7 of serotype G1 or G3. In mice immunized parenterally twice, G3 virus-like particles (VLPs) induced a homotypic, whereas G1 VLPs induced a homotypic and heterotypic (G3) serum neutralizing immune response. Administration of three doses of G1 or G3 VLPs induced serum antibodies that neutralized five of seven different serotype test viruses. The inclusion of VP4 in the VLPs was not essential for the induction of heterotypic neutralizing antibody in mice. To confirm these results in another species, rabbits were immunized parenterally with two doses of 2/4/6/7-VLPs containing a G3 or G1 VP7, sequentially with G3 VLPs followed by G1 (G3/G1) VLPs, or with live or psoralen-inactivated SA11. High-titer homotypic serum neutralizing antibody was induced in all rabbits, and low-level heterotypic neutralizing antibody was induced in a subset of rabbits. The rabbits immunized with the G1 or G3/G1 VLPs in QS-21 were challenged orally with live G3 ALA rotavirus. Protection levels were similar in rabbits immunized with homotypic G3 2/4/6/7-VLPs, heterotypic G1 2/4/6/7-VLPs, or G3/G1 2/4/6/7-VLPs. Therefore, G1 2/4/6/7-VLPs can induce protective immunity against a live heterotypic rotavirus challenge in an adjuvant with potential use in humans. Following challenge, broad serum heterotypic neutralizing antibody responses were detected in rabbits parenterally immunized with G1, G3/G1, or G3 VLPs but not with SA11. Immunization with VLPs may provide sufficient priming of the immune system to induce protective anamnestic heterotypic neutralizing antibody responses upon subsequent rotavirus infection. Therefore, a limited number of serotypes of VLPs may be sufficient to provide a broadly protective subunit vaccine.
Collapse
Affiliation(s)
- S E Crawford
- Division of Molecular Virology, Baylor College of Medicine, Houston, Texas 77030, USA
| | | | | | | | | | | | | |
Collapse
|
11
|
Gorrell RJ, Bishop RF. Homotypic and heterotypic serum neutralizing antibody response to rotavirus proteins following natural primary infection and reinfection in children. J Med Virol 1999. [DOI: 10.1002/(sici)1096-9071(199902)57:2<204::aid-jmv20>3.0.co;2-y] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
12
|
Matson DO. Protective immunity against group A rotavirus infection and illness in infants. ARCHIVES OF VIROLOGY. SUPPLEMENTUM 1996; 12:129-139. [PMID: 9015110 DOI: 10.1007/978-3-7091-6553-9_15] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
Abstract
Understanding of the protective effect provided by natural rotavirus infections against subsequent rotavirus infections is required for evaluating vaccine development programs. Prior studies of the protective efficacy of natural infections and correlates of natural protection are reviewed and results from several studies presented only in abstract form are summarized to provide a current assessment of knowledge in this area. Six cohort studies have reported rates for the protective efficacy of a natural rotavirus infection against subsequent infection, diarrhea, or severe diarrhea. These efficacy estimates ranged from 0 to 100% and are not directly comparable because of differences in methodology and population monitored. Results from other study designs also have been confusing, until recently. Recent studies have identified immunologic correlates of protection and studies from a cohort of intensely monitored Mexican children promise to provide a comprehensive assessment of the strength of the protective effect of natural rotavirus infection.
Collapse
Affiliation(s)
- D O Matson
- Center for Pediatric Research, Children's Hospital of The king's Daughters, Norfolk, Virginia, USA
| |
Collapse
|
13
|
Muñoz M, Lanza I, Alvarez M, Cármenes P. Prevalence of neutralizing antibodies to 9 rotavirus strains representing 7 G-serotypes in sheep sera. Vet Microbiol 1995; 45:351-61. [PMID: 7483248 DOI: 10.1016/0378-1135(95)00002-r] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Neutralizing antibodies to 9 rotavirus strains representing serotypes G1, G3, G5, G6, G8, G9, and G10 were investigated in 212 ovine serum samples from 3 age groups, 1-week-old lambs, 2- to 3-months-old lambs and adult sheep. All sera from 1-week-old lambs had neutralizing antibodies to all 9 rotavirus strains. Both neutralizing antibody titers and prevalences to all 9 strains markedly decreased in the 2- to 3-months-old lamb group and increased again in the adult sheep group. Also, adult sheep sera neutralized a larger number of rotavirus strains than 2- to 3-months-old lamb sera. The highest neutralizing antibody titers and prevalences were found to strains B223 and K923, representing serotype G10, to strain RRV, representing serotype G3, and to strain NCDV, representing serotype G6, indicating that these could be the predominant 3 rotavirus serotypes in Spanish sheep. The rotavirus serotypes infecting sheep observed by us differ from those described for cattle, where G6 is the most prevalent serotype followed by G10, and G3 has been seldom found. Very low prevalences were observed for strains WA and OSU representing serotypes G1 and G5 respectively, suggesting that they probably do not infect sheep and neutralizing antibodies found are derived from heterotypic responses to other serotypes. Intermediate prevalences and titers were found to strains UK (serotype G6), 69M (serotype G8) and WI61 (serotype G9). Neutralizing antibodies distinguished between different strains sharing their VP7 specificity: B223 and K923, a bovine and an ovine serotype G10 strains, and NCDV and UK, two serotype G6 bovine rotavirus strains with different VP4 antigen.
Collapse
Affiliation(s)
- M Muñoz
- Departamento de Sanidad Animal (Enfermedades Infecciosas y Epidemiología), Facultad de Veterinaria, Universidad de León, Spain
| | | | | | | |
Collapse
|
14
|
Snodgrass DR, Campbell I, Mwenda JM, Chege G, Suleman MA, Morein B, Hart CA. Stimulation of rotavirus IgA, IgG and neutralising antibodies in baboon milk by parenteral vaccination. Vaccine 1995; 13:408-13. [PMID: 7793139 PMCID: PMC7130768 DOI: 10.1016/0264-410x(95)98265-c] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/1994] [Revised: 11/07/1994] [Accepted: 11/18/1994] [Indexed: 01/27/2023]
Abstract
A rhesus rotavirus vaccine adjuvanted with ISCOMs was injected intramuscularly to 5 pregnant baboons, with repeated doses 1-2 and 14 weeks after delivery. Maternal blood and milk samples and blood samples from their babies were collected at 2-weekly intervals until 26 weeks after parturition. Samples were assayed for rotavirus antibodies by ELISAs and neutralisation tests. Vaccination produced statistically significant increases in maternal serum IgG and neutralising antibodies, and in milk IgA, IgG, and neutralising antibodies. Control baboon mothers sampled from 12 weeks after delivery had lower serum and milk antibody titres, but responded to vaccination at 16 weeks by producing a similar antibody profile in serum and milk to those previously vaccinated. Because of the endemic nature of human rotaviral infections, similar maternal vaccinations have potential as a means of increasing milk antibodies to a level at which they may be protective to infants.
Collapse
|
15
|
Matson DO, O'Ryan ML, Pickering LK, Estes MK. Assessment of epitope-blocking assays for measuring antibody to rotavirus. J Virol Methods 1994; 48:293-300. [PMID: 7527405 DOI: 10.1016/0166-0934(94)90128-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Criteria for determining the presence of antibody and of a response to infection in the epitope-blocking assay for anti-rotavirus antibody were evaluated using 222 sera from children younger than 30 months of age. The children were monitored for rotavirus diarrhea by means of daily symptom records and weekly stool specimen collection, whether or not symptoms occurred. Sera were collected at 6-month intervals. Forty-three serum pairs were collected before and after documented rotavirus infections. The remaining 136 sera were collected from children with no identified infections in the monitoring interval. Use of a 50% cutoff-point, as in prior reports, was too stringent a criterion for determining the presence of blocking antibody. The absolute percent blocking at the 1:10 serum dilution was a better measure of antibody content than end-point titration using the 50% cutoff-point.
Collapse
Affiliation(s)
- D O Matson
- Department of Pediatrics, Baylor College of Medicine, Houston, TX
| | | | | | | |
Collapse
|
16
|
Affiliation(s)
- Y Hoshino
- Epidemiology Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892
| | | |
Collapse
|
17
|
Abstract
The development of a successful rotavirus vaccine is a complex problem. Our review of rotavirus vaccine development shows that many challenges remain, and priorities for future studies need to be established. For example, the evaluation of administration of a vaccine with OPV or breast milk might receive less emphasis until a vaccine is made that shows clear efficacy against all virus serotypes. Samples remaining from previous trials should be analyzed to determine epitope-specific serum and coproantibody responses to clarify why only some trials were successful. Detailed evaluation of the antigenic properties of the viruses circulating and causing illness in vaccinated children also should be performed for comparisons with the vaccine strains. In future trials, sample collection should include monitoring for asymptomatic infections and cellular immune responses should be analyzed. The diversity of rotavirus serotype distribution must be monitored before, during, and after a trial in the study population and placebo recipients must be matched carefully to vaccine recipients. Epidemiologic and molecular studies should be expanded to document, or disprove, the possibility of animal to human rotavirus transmission, because, if this occurs, vaccine protection may be more difficult in those areas of the world where cohabitation with animals occurs. We also need to have an accurate assessment of the rate of protection that follows natural infections. Is it realistic to try to achieve 90% protective efficacy with a vaccine if natural infections with these enteric pathogens only provide 60% or 70% protection? Subunit vaccines should be considered to be part of vaccine strategies, especially if maternal antibody interferes with the take of live vaccines. The constraints on development of new vaccines are not likely to come from molecular biology. The challenge remains whether the biology and immunology of rotavirus infections can be understood and exploited to permit effective vaccination. Recent advances in developing small animal models for evaluation of vaccine efficacy should facilitate future vaccine development and understanding of the protective immune response(s) (Ward et al. 1990b; Conner et al. 1993).
Collapse
Affiliation(s)
- M E Conner
- Division of Molecular Virology, Baylor College of Medicine, Houston, TX 77030
| | | | | |
Collapse
|
18
|
Abstract
Rotaviruses cause gastroenteritis in neonates of many animal species including cattle, swine, horses, dogs, cats, chickens and turkeys. Rotavirions are nonenveloped, are about 75 nm in diameter, have a double capsid, and contain 11 double-stranded RNA segments as their genome. Several antigenically distinct groups of rotaviruses have been identified and have been alphabetically designated as A through G. Group A rotaviruses were the first group of rotaviruses isolated and are the most commonly detected rotaviruses in diarrheic animals. Group A rotaviruses have two surface proteins, VP4 and VP7, both of which are important in serotype determination and in inducing neutralizing antibodies and protective immunity. Multiple serotypes of group A rotavirus based on glycoprotein VP7 (designated as G types) and based on VP4 (P types) have been identified. The immune response to rotaviruses is essentially serotype specific, however, cross-reactive or heterotypic epitopes have also been identified. Currently acceptable methods for immunogen quantitation include the induction of neutralizing antibody in host or laboratory animals. The in vivo efficacy of vaccines against rotavirus-associated gastroenteritis remains the standard method against which in vitro methods must be compared. Several animal models have been developed which could potentially be used in evaluating the efficacy of candidate vaccines. Monoclonal antibodies to rotavirus immunogens are also currently available and serve as valuable reagents for in vitro quantitation of rotaviral immunogens.
Collapse
Affiliation(s)
- P S Paul
- Veterinary Medical Research Institute, College of Veterinary Medicine, Iowa State University, Ames 50011
| | | |
Collapse
|
19
|
Xu Z, Hardy ME, Williams JD, Woode GN, Ramig RF. Immunodominant neutralizing antigens depend on the virus strain during a primary immune response in calves to bovine rotaviruses. Vet Microbiol 1993; 35:33-43. [PMID: 8395744 DOI: 10.1016/0378-1135(93)90114-m] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Sera obtained from gnotobiotic calves (GC antisera) infected with bovine rotavirus strain NCDV or B223 from a previous study (Woode et al., 1987), which have different G (G6 and G10 respectively) and P serotypes, were compared for their neutralization (NT) properties to a number of human and animal rotaviruses (representing G serotype 1-6, 8-10). Two distinct patterns of neutralization were identified from these GC antisera. Of all the serotypes tested, NCDV GC antisera neutralized only B641 to a relatively high titer compared with the homologous titer, implying a narrow pattern of NT response. Analysis with reassortants indicated that the response was primarily to VP4. In contrast, B223 GC antisera neutralized most of the G serotypes tested to titers within 3-7 fold of the homologous titer, demonstrating a broad pattern of NT response. In the earlier study B223 was shown to induce a heterotypic protection against bovine rotavirus B641 (G serotype 6), and the serologic data obtained from this study indicates that a B223 vaccine might provide broad protection against several different serotypes of human and animal rotaviruses.
Collapse
Affiliation(s)
- Z Xu
- Department of Veterinary Pathobiology, College of Veterinary Medicine, Texas A&M University, College Station 77843-4467
| | | | | | | | | |
Collapse
|
20
|
Cornaglia EM, Elazhary YM, Brodeur BR, Talbot BG. Monoclonal anti-idiotype induces antibodies against bovine Q17 rotavirus. J Virol 1992; 66:5763-9. [PMID: 1326641 PMCID: PMC241451 DOI: 10.1128/jvi.66.10.5763-5769.1992] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
This study describes, for the first time, the production and use of an "internal-image" anti-idiotypic monoclonal antibody (MAb) to elicit a rotavirus-specific antibody response. An immunoglobulin G2a MAb, designated RQ31 (MAb1), specific for the outer capsid protein VP4 of bovine Q17 rotavirus and capable of neutralizing viral infection in vitro was used to generate an anti-idiotypic MAb (MAb2). This MAb2, designated RQA2, was selected by enzyme-linked immunosorbent assay (ELISA) using F(ab')2 fragments of RQ31. RQA2 (MAb2) inhibited the binding of RQ31 (MAb1) to the virus but had no effect on the binding of other rotavirus-specific MAbs. The MAb2 also inhibited virus neutralization mediated by MAb1 in a dose-dependent fashion. Naive guinea pigs immunized with the MAb2 produced anti-anti-idiotypic antibodies (Ab3) that reacted with bovine Q17 rotavirus in an ELISA and neutralized rotavirus infection in vitro. The Ab3 response was characterized as MAb1-like because the Ab3 recognizes only the Q17 and neonatal calf diarrhea virus rotavirus strains in ELISA, as did RQ31 (MAb1). The Ab3 response also possessed two other characteristics of RQ31: the abilities to bind the 1.36 (double-capsid) but not the 1.38 (single-capsid) purified rotavirus fraction in ELISA and to immunoprecipitate the VP4 rotavirus protein.
Collapse
Affiliation(s)
- E M Cornaglia
- Virology Section, Faculty of Veterinary Medicine, University of Montreal, Saint-Hyacinthe, Quebec, Canada
| | | | | | | |
Collapse
|